Agent based modeling of the effects of potential treatments over the blood-brain barrier in multiple sclerosis

Journal of Immunological Methods

Volumn 427, Issue , 2015, Pages 6-12

  Pennisi, Marzio ^a   Russo, Giulia ^a   Motta, Santo ^a   Pappalardo, Francesco ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

ABM; BBB; Modeling; Multiple sclerosis

Indexed keywords

CYTOKINE; VITAMIN D; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; MYELIN; REACTIVE OXYGEN METABOLITE; TIGHT JUNCTION PROTEIN; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; MULTIPLE SCLEROSIS; NERVE FIBER; PRIORITY JOURNAL; RELAPSE; REMISSION; SIMULATION; COMPUTER MODEL; CYTOKINE RELEASE; DISEASE COURSE; EFFECTOR CELL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; LYMPHOCYTE; MEMORY T LYMPHOCYTE; NONHUMAN; OLIGODENDROGLIA; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; COMPUTER SIMULATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

BLOOD-BRAIN BARRIER; COMPUTER SIMULATION; HUMANS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; VITAMIN D;

EID: 84952636655     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2015.08.014     Document Type: Article

References (72)

1. Ascherio A., Munger K.L., Lennette E.T., Spiegelman D., Hernán M.A., Olek M.J., Hankinson S.E., Hunter D.J. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. J. Am. Med. Assoc. 2001, 286(24):3083.
2. Ballabh P., Braun A., Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 2004, 16:1.
3. Bhalla A., Amento E., Glimcher B.S.L. 1,25-Dihydroxyvitamin d3 inhibits antigen-induced T cell activation. J. Immunol. 1984, 133(4):1748.
4. Bianca C., Pappalardo F., Pennisi M., Motta S., Ragusa M.A. Persistence analysis in a Kolmogorov-type Model for Cancer-Immune System Competition Numerical Analysis and Applied Mathematics ICNAAM 2013. AIP Conf. Proc. to 1389 2013, 945.
5. Biernacki K., Prat A., Blain M., Antel J.P. Regulation of cellular and molecular trafficking across human brain endothelial cells by Th1- and Th2- polarized lymphocytes. J. Neuropathol. Exp. Neurol. 2004, 63:223.
6. Carneiro J., Leon K., Caramalho I., van den Dool C., Gardner R., Oliveira V., Bergman M.L., Sepúlveda N., Paixão T., Faro J., Demengeot J. When three is not a crowd: a crossregulation model of the dynamics and repertoire selection of regulatory CD4+ T cells. Immunol. Rev. 2007, 216:48.
7. Chiacchio F., Pennisi M., Russo G., Motta S., Pappalardo F. Agent based modeling of the immune system: NetLogo, a promising framework. BioMed Res. Int. 2014, 2014. 10.1155/2014/907171.
8. Christensen J.R., Börnsen L., Khademi M., Olsson T., Jensen P.E., Sørensen P.S., Sellebjerg F. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Mult. Scler. 2013, 19(7):877.
9. Chui R., Dorovini-Zis K. Regulation of CCL2 and CCL3 expression in human brain endothelial cells by cytokines and lipopolysaccharide. J. Neuroinflammation 2010, 7:1.
10. Cocco E., Marrosu M.G. The current role of mitoxantrone in the treatment of multiple sclerosis. Expert. Rev. Neurother. 2014, 14:607.
11. Compston A., McDonald I., Noseworthy J., Lassmann H., Miller D., Smith K., Wekerle H., Confavreux C. McAlpine's Multiple Sclerosis 2005, 4. Elsevier.
12. Durelli L., Conti L., Clerico M., Boselli D., Contessa G., Ripellino P., Ferrero B., Eid P., Novelli F. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann. Neurol. 2009, 65:499.
13. Engelhardt B. Molecular mechanisms involved in T cell migration across the blood-brain barrier. J. Neural Transm. 2006, 113:477.
14. Ensoli F., Fiorelli V., Lugaresi A., Farina D., De Cristofaro M., Collacchi B., Muratori D.S., Scala E., Di Gioacchino M., Paganelli R., et al. Lymphomononuclear cells from multiple sclerosis patients spontaneously produce high levels of oncostatin M, tumor necrosis factors alpha and beta, and interferon gamma. Mult. Scler. 2002, 8:284.
15. Fontenot J.D., Rudensky A.Y. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat. Immunol. 2005, 6(4):331.
16. Frisullo G., Nociti V., Iorio R., Patanella A.K., Marti A., Caggiula M., Mirabella M., Tonali P.A., Batocchi A.P. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. Cytokine 2008, 44:22.
17. Gilgun-Sherki Y., Melamed E., Offen D. The role of oxidative stress in the pathogenesis of multiple sclerosis: the need for effective antioxidant therapy. J. Neurol. 2004, 251:261.
18. Goodin D.S. The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS One 2009, 4(2):e4565. 10.1371/journal.pone.0004565.
19. Gorman S., Kuritzky L., Judge M., Dixon K., McGlade J., Mason R., Finlay-Jones J., Hart P. Topically applied 1,25-dihydroxyvitamin d3 enhances the suppressive activity of cd4+cd25+ cells in the draining lymph nodes. J. Immunol. 2007, 179(9):6273.
20. Gregori S., Casorati M., Amuchastegui S., Smiroldo S., Davalli A., Adorini L. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin d3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol. 2001, 167(4):1945.
21. Hendrikis J.J.J., van Meeteren M.E., van Der Pol S.M., Newman T.A., Dijkstra C.D., de Vries H.E. Axonal damage and oxidative stress duin chronic experimental allergic encephalomyelitis. Int. J. Neuroprotect. Neurogen. 2005, 1:171.
22. Hendriks J.J.J., Alblas J., Van Der Pol S.M.A., van Tol E.A.F., Dijkstra C.D., de Vries H.E. Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. J. Exp. Med. 2004, 200:1667.
23. Hickey W.F. Basic principles of immunological surveillance of the normal central nervous system. Glia 2001, 36:118.
24. Hohnoki K., Inoue A., Koh C.S. Elevated serum levels of IFN- gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J. Neuroimmunol. 1998, 87:27.
25. Holman D.W., Klein R.S., Ransohoff R.M. The blood-brain barrier, chemokines and multiple sclerosis. Biochim. Biophys. Acta 2011, 1812:220.
26. Ifergan I., Wosik K., Cayrol R., Kebir H., Auger C., Bernard M., Bouthillier A., Moumdjian R., Duquette P., Prat A. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann. Neurol. 2006, 60:45.
27. Kahl K.G., Kruse N., Toyka K.V., Rieckmann P. Serial analysis of cytokine mRNA profiles in whole blood samples from patients with early multiple sclerosis. J. Neurol. Sci. 2002, 200:53.
28. Kremenchutzky M., Rice G.P.A., Baskerville J., Wingerchuk D.M., Ebers G.C. The natural history of multiple sclerosis: a geographically based study. 9: observations on the progressive phase of the disease. Brain 2006, 129(3):584.
29. Kyewski B., Klein L. A central role for central tolerance. Annu. Rev. Immunol. 2006, 24:571.
30. La Mantia L., Munari L.M., Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane Database Syst. Rev. 2010, (5).
31. Larochelle C., Alvarez J.I., Prat A. How do immune cells overcome the blood-brain barrier in multiple sclerosis?. FEBS Lett. 2011, 585:3770.
32. Lehmann D., Karussis D.M., Misrachi-Koll R., Shezen E., Ovadia H., Abramsky O. Oral administration of the oxidant-scavenger N-acetyl-L-cysteine inhibits acute experimental autoimmune encephalomyelitis. J. Neuroimmunol. 1994, 50:35.
33. Liu Y., Zhu B., Wang X., Luo L., Li P., Paty D.W., Cynader M.S. Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. J. Neuroimmunol. 2003, 139:27.
34. Lombardi A., Cantini G., Piscitelli E., Gelmini S., Francalanci M., Mello T., Ceni E., Varano G., Forti G., Rotondi M., et al. A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:718.
35. Lombardi A., Cantini G., Mello T., Francalanci M., Gelmini S., Cosmi L., Santarlasci V., Degl'Innocenti S., Luciani P., Deledda C., et al. Molecular mechanisms underlying the pro-inflammatory synergistic effect of tumor necrosis factor alpha and interferon gamma in human microvascular endothelium. Eur. J. Cell Biol. 2009, 88:731.
36. Ludowyk P.A., Willenborg D.O., Parish C.R. Selective localisation of neuro-specific T lymphocytes in the central nervous system. J. Neuroimmunol. 1992, 37:237.
37. Lund J.M., Hsing L., Pham T.T., Rudensky A.Y. Coordination of early protective immunity to viral infection by regulatory T cells. Science 2008, 320(5880):1220.
38. Man S., Ubogu E.E., Ransohoff R.M. Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathol. 2007, 17:243.
39. Marracci G., Jones H.R.E., McKeon G.P., Bourdette D.N. Alpha lipoic acid inhibits T cell migration into the spinal cord and suppresses and treats experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2002, 131:104.
40. Minagar A., Alexander J.S. Blood-brain barrier disruption in multiple sclerosis. Mult. Scler. 2003, 9:540.
41. Mirshafiey A., Mohsenzadegan M. Antioxidant therapy in multiple sclerosis. Immunopharmacol. Immunotoxicol. 2009, 31:13.
42. Morini M., Roccatagliata L., Dell'Eva R., Pedemonte E., Furlan R., Minghelli S., Giunti D., Pfeffer U., Marchese M., Noonan D. Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2004, 148:146.
43. Motta S., Pappalardo F. Mathematical modeling of biological systems. Brief. Bioinform. 2013, 14(4):411.
44. Mrass P., Weninger W. Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. Immunol. Rev. 2006, 213:195.
45. Nagyoszi P., Wilhelm I., Farkas A.E., Fazakas C., Dung N.T., Hasko J., Krizbai I.A. Expression and regulation of toll-like receptors in cerebral endothelial cells. Neurochem. Int. 2010, 57:556.
46. Owens T., Bechmann I., Engelhardt B. Perivascular spaces and the two steps to neuroinflammation. J. Neuropathol. Exp. Neurol. 2008, 67:1113.
47. Ozenci V., Kouwenhoven M., Huang Y.M., Kivisakk P., Link H. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment. Clin. Exp. Immunol. 2000, 120:147.
48. Pappalardo F., Mastriani E., Lollini P.-L., Motta S. Genetic algorithm against cancer. In 6th International Workshop on Fuzzy Logic and Applications (WILF 2005). Lect. Notes Comput. Sci 2006, 3849:223.
49. Pappalardo F., Palladini A., Pennisi M., Castiglione F., Motta S. Mathematical and computational models in tumor immunology. Math. Model. Nat. Phenom. 2012, 7(3):186.
50. Pappalardo F., Pennisi M., Rajput A.-M., Chiacchio F., Motta S. Relapsing-remitting multiple scleroris and the role of vitamin D: an agent based model. Proceedings of the 5th ACM Conference on Bioinformatics, Computational Biology and Health Informatics (ACM-BCB 2014) 2014, 744.
51. Pappalardo F., Flower D., Russo G., Pennisi M., Motta S. Computational modelling approaches to vaccinology. Pharmacol. Res. 2014, 40. 10.1016/j.phrs.2014.08.006.
52. Pennisi M., Pappalardo F., Motta S. Agent based modeling of lung metastasis-immune system competition. Lect. Notes Comput. Sci 2009, 5666:1.
53. Pennisi M., Rajput A.-M., Toldo L., Pappalardo F. Agent based modeling of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis. BMC Bioinforma. 2013, 14(Suppl. 16):S9.
54. Ponsonby A.L., van der Mei I., Dwyer T., Blizzard L., Taylor B., Kemp A., Simmons R., Kilpatrick T. Exposure to infant siblings during early life and risk of multiple sclerosis. J. Am. Med. Assoc. 2005, 293(4):463.
55. Raine C.S., Cannella B., Duijvestijn A.M., Cross A.H. Homing to central nervous system vasculature by antigen-specific lymphocytes. II. Lymphocyte/endothelial cell adhesion during the initial stages of autoimmune demyelination. Lab. Investig. 1990, 63:476.
56. Ramagopalan S.V., Maugeri N.J., Handunnetthi L., Lincoln M.R., Orton S.M., Dyment D.A., DeLuca G.C., Herrera B.M., Chao M.J., Sadovnick A.D., Ebers G.C., Knight J.C. Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet. 2009, 5(2):e1000369. 10.1371/journal.pgen.1000369.
57. Ransohoff R.M. Natalizumab for multiple sclerosis. N. Engl. J. Med. 2007, 356:2622.
58. Ruuls S.R., Bauer J., Sontrop K., Huitinga I., 't Hart B.A., Dijkstra C.D. Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J. Neuroimmunol. 1995, 56:207.
59. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155(3):1151.
60. Seguin R., Biernacki K., Rotondo R.L., Prat A., Antel J.P. Regulation and functional effects of monocyte migration across human brain-derived endothelial cells. J. Neuropathol. Exp. Neurol. 2003, 62:412.
61. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683.
62. Subileau E.A., Rezaie P., Davies H.A., Colyer F.M., Greenwood J., Male D.K., Romero I.A. Expression of chemokines and their receptors by human brain endothelium: implications for multiple sclerosis. J. Neuropathol. Exp. Neurol. 2009, 68:227.
63. Sundström P., Juto P., Wadell G., Hallmans G., Svenningsson A., Nyström L., Dillner J., Forsgren L. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 2004, 62(12):2277.
64. Tsuge M., Yasui K., Ichiyawa T., Saito Y., Nagaoka Y., Yashiro M., Yamashita N., Morishima T. Increase of tumor necrosis factor-alpha in the blood induces early activation of matrix metalloproteinase-9 in the brain. Microbiol. Immunol. 2010, 54:417.
65. van Boxel-Dezaire A.H., Smits M., van Trigt-Hoff S.C., Killestein J., van Houwelingen J.C., Polman C.H., Nagelkerken L. Cytokine and IL-12 receptor mRNA discriminate between different clinical subtypes in multiple sclerosis. J. Neuroimmunol. 2001, 120:152.
66. van der Goes A., Wouters D., Van Der Pol S.M., Huizinga R., Ronken E., Adamson P., Greenwood J., Dijkstra C.D., De Vries H.E. Reactive oxygen species enhance the migration of monocytes across the blood-brain barrier in vitro. FASEB J. 2001, 15:1852.
67. Vélez de Mendizábal N., Carneiro J., Solé R.V., Goñi J., Bragard J., Martinez-Forero I., Martinez-Pasamar S., Sepulcre J., Torrealdea J., Bagnato F., Garcia-Ojalvo J., Villoslada P. Modeling the effector-regulatory T cell cross-regulation reveals the intrinsic character of relapses in multiple sclerosis. BMC Syst. Biol. 2011, 5:114. (http://www.biomedcentral.com/1752-0509/5/114).
68. Vladimirova O., O'Connor J., Cahill A., Alder H., Butunoi C., Kalman B. Oxidative damage to DNA in plaques of MS brains. Mult. Scler. 1998, 4:413.
69. Wosik K., Biernacki K., Khouzam M.P., Prat A. Death receptor expression and function at the human blood-brain barrier. J. Neurol. Sci. 2007, 259:53.
70. Wu Y., Zhu W.Q. Stochastic analysis of a pulse-type prey-predator model. Phys. Rev. E Stat. Nonlinear Soft Matter Phys. 2008, 77(4 Pt 1):041911.
71. Yoav S., Leyton-Brown K. Multiagent Systems: Algorithmic, Game-Theoretic, and Logical Foundations 2009, 504. Cambridge University Press.
72. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57:178.